” says Juanita Lopez, from the Institute of Cancer Research. “This encouraging early study suggests some patients with advanced brain cancer who are EB1-positive could be treated with lisavanbulin, a targeted drug which blocks
Yuile PG,Tran MH.Survival with brain metastases following radiation therapy [J].Australas Radiol,2002,46(4):390-395.Yuile,PG,Tran,MH.Survival with brain metastases following radiation therapy. Australasian Radiology . 2002Yuile PG, Tran MH. Survival with brain metastases following radiation therapy....
Find all the latest on cancer therapy at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.
Novocure’s Tumor Treating Fields: Innovative brain cancer therapy with survival and safety benefitsIntroduction to brain cancer research at Novocure By Uri Weinberg Produced by Twitter Facebook Email The three most common types of brain tumour are intracranial metastases, which spread from other ...
WASHINGTON --Although it sounds like science fiction, a cap-like device that makes electric fieldsto fight cancerimproved survival for the first time in more than a decade for people with deadly brain tumors, final results of a large study suggest. ...
brain barrier, rendering them a promising means of delivering drugs to treat brain tumors.114,115In a recent study, neutrophils were utilized to deliver paclitaxel (PTX)-loaded liposomes to the brain, leading to the suppression of post-surgical glioma recurrence and improved survival rates in mice...
The researchers found no differences between the two groups in survival and cancer control, suggesting that proton therapy was just as effective in treating the cancer even as it caused fewer side effects. Overall survival at one year for the proton therapy group was 83 percent as against 81 pe...
1 The event rate in the SOLD study was lower than expected because 60% of the patients had node-negative cancer. In studies with low event rates, common methods of analysis all have limitations, and one is guided by both pragmatic considerations and clinical interpretations. We increased the ...
Mathematical modeling may potentially serve to bridge molecular/cellular mechanisms of drug resistance and population-level patient survival and facilitates the quantitative evaluation and optimization of combination therapeutics and cancer clinical trial design. Many mathematical and computational models have ...
cancer. In this study, 1 patient had a sustained response of more than 13 months while 6 had stable disease, and 2 had progressed disease. The median progression-free survival was 7.13 months, with a median overall survival of 15.63 months [60]. This study showed that the non-...